4 completed, 3 active not recruiting. 5 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Active not recruiting 3, Completed 2 |
| Phase 1 | 4 | Completed 4 |
Follow GSK2636771: new trials by email Literature Review of GSK2636771 trials Research Report on GSK2636771
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss GSK2636771, Pembrolizumab - Melanoma and Other Malignant Neoplasms of Skin, Metastatic Melanoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 28 | 2017-07-17 | 2026-08-27 |
| Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N) PI3K-beta Inhibitor GSK2636771 - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 24 | 2016-05-05 | 2026-05-27 |
| Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P) PI3K-beta Inhibitor GSK2636771 - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 35 | 2016-03-21 | 2026-05-27 |
| PI3Kβ Selective Inhibitor With Paclitaxel, Advanced Gastric Adenocarcinoma GSK2636771, Paclitaxel - Advanced Gastric Adenocarcinoma | Phase 1 / Phase 2 | Completed | Yonsei University | 42 | 2016-02-01 | 2025-01-24 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Adavosertib, Afatinib, Afatinib Dimaleate - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 6452 | 2015-08-17 | 2026-10-26 |
| Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer GSK2636771, Enzalutamide - Neoplasms | Phase 1 | Completed | GlaxoSmithKline | 37 | 2014-11-13 | 2020-10-22 |
| A Phase I/IIa, First Time in Human, Study of GSK2636771 in Subjects With Advanced Solid Tumors With Phosphatase and Tensin Homolog (PTEN) Deficiency GSK2636771 - Cancer | Phase 1 | Completed | GlaxoSmithKline | 30 | 2011-11-10 | 2018-07-24 |
Hematologic Neoplasms (3) · Lymphoma (3) · Multiple Myeloma (3) · Melanoma (2) · Neoplasms (2) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Renal Cell (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Glioma (1) · Lung Neoplasms (1) · Ovarian Neoplasms (1)
National Cancer Institute (NCI) (3) · GlaxoSmithKline (2) · M.D. Anderson Cancer Center (1) · Yonsei University (1)
United States (6) · South Korea (2) · United Kingdom (2) · Guam (1) · Puerto Rico (1)
Filip Janku (2) · Hussein Tawbi, MD, PHD (1) · Keith T Flaherty (1) · Sun Young Rha (1)
PMID 26586415, PMID 32463741, PMID 33048619, PMID 34281912, PMID 35133871, PMID 35138919, PMID 36351402, PMID 37053535, PMID 37322121, PMID 37934000, PMID 38591867, PMID 39666929, PMID 39693587, PMID 39913886, PMID 40865033, PMID 41066729
U10CA180820 (3), U24CA196172 (3)